Opthea Limited (AU:OPT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opthea Limited, a biopharmaceutical company, is set to showcase its promising wet AMD treatment, sozinibercept, at two major ophthalmology events. The company’s innovative therapy, which combines sozinibercept with ranibizumab, has shown significantly improved visual outcomes in recent trials, sparking interest among investors and stakeholders in the ophthalmic market.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.